Explore

Trendline Trendline
Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology

Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology

Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology
Trendline Trendline
Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development
Trendline Trendline
Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions

Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions

Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth

Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth

Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth
Trendline Trendline
Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth

Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth

Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth
Trendline Trendline
Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage

Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage

Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment

Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment

Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities